Enlightenment through smart measurements

Open menu

News & Events

OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure

13 October 2021

OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure Quebec, Quebec, October 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire,…

Read more

OpSens Presents at Lytham Partners Fall Conference

5 October 2021

OpSens to Present at the Lytham Partners Fall 2021 Investor Conference – Tuesday, October 5, 2021, 9:30 AM

29 September 2021

OPSENS TO PRESENT AT THE LYTHAM PARTNERS FALL 2021 INVESTOR CONFERENCE Presentation at 9:30 AM, Tuesday October 5, 2021  Quebec, Quebec, September 29, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at…

Read more

OpSens Receives Approval from Health Canada to Initiate First In-Man Study For its New Guidewire For the TAVR Procedure

20 September 2021

OPSENS RECEIVES APPROVAL FROM HEALTH CANADA TO INITIATE FIRST IN-MAN STUDY FOR ITS NEW GUIDEWIRE FOR THE TAVR PROCEDURE SAVVYWIRE, the first guidewire that aims to improve procedural efficiency and clinical outcomes for patients undergoing minimally invasive, Trans Aortic Valve Replacement (TAVR) Quebec, Quebec, September 20, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF)…

Read more

OpSens Appoints Lori Chmura to its Board of Directors

8 September 2021

OpSens Appoints Lori Chmura to its Board of Directors Quebec City, Quebec, September 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today announced the appointment of Lori Chmura to its board of Directors, effective September 8….

Read more

Conference Call Q3

13 July 2021

OpSens Announces Third Quarter Fiscal 2021 Record Financial Results

13 July 2021

OpSens Announces Third Quarter Fiscal 2021 Record Financial Results Conference call on the results to be held today at 11 a.m. Quebec City, Quebec, July 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today reported its…

Read more

OpSens to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesday, July 13

7 July 2021

OpSens to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesday, July 13, 2021  Conference call to be conducted at 11:00 am ET Quebec City, Quebec, July 7, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical…

Read more

OpSens Solutions Receives Funding Support to Jointly Develop an Optical-Based Fuel Monitoring System for Aerospace Applications, Including Civil Aircrafts

16 June 2021

OpSens Solutions Receives Funding Support to Jointly Develop an Optical-Based Fuel Monitoring System for Aerospace Applications, Including Civil Aircrafts Quebec City, Quebec, June 16, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today announced that OpSens Solutions Inc. (“OpSens Solutions”), its wholly-owned subsidiary, is receiving advisory services and up to $500,000 in funding support…

Read more

OpSsens Will Participate and Present at Two Investment Conferences Lytham Partners and Raymond James

9 June 2021

OPSENS WILL PARTICIPATE AND PRESENT AT TWO INVESTMENT CONFERENCES Lytham Partners and Raymond James Quebec City, Quebec, June 9, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that it will present at…

Read more